Q32 Bio stock soared after its alopecia drug cleared a key clinical bar

The biotech's Phase 2a study of bempikibart showed a 35.3% mean reduction in hair loss scores, with the company planning a registration-directed program by early 2027

SOPA Images / Getty Images

Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata on Monday, a disclosure that propelled shares $9.30 higher — an 83% gain — to a closing price of $20.51.

The trial's primary efficacy endpoint was met, with the prespecified modified intent-to-treat population posting a mean 35.3% drop in Severity of Alopecia Tool scores relative to baseline by the 36-week mark, the company said. Within that population, 40% of patients hit the SALT-20 threshold — defined as........

© Quartz